Hulk Hogan, wrestling icon, dies at 71 in Florida home
Cathie Wood’s ARK ETF published their daily trades for Tuesday, May 6th, 2025, revealing a series of strategic moves in the biotech and tech sectors. Leading the day’s transactions was a significant sell-off of Palantir Technologies Inc (NYSE:NASDAQ:PLTR) shares, with ARK’s ARKK ETF parting with 376,874 shares valued at approximately $46.65 million. This move marks a continuation of ARK’s recent reduction in its Palantir position, following a pattern of sales of the data analytics company’s stock over the past week.
Conversely, ARK showed a strong buying interest in Guardant Health Inc (NASDAQ:GH), adding 237,374 shares to its ARKK ETF at a total cost of over $10.45 million. This purchase aligns with ARK’s bullish stance on the precision oncology company, as it has consistently increased its holdings in GH over recent trading sessions.
Another notable investment was in Twist Bioscience Corp (NASDAQ:TWST), with ARK acquiring 283,186 shares through its ARKK ETF, amounting to roughly $10.17 million. This trade underscores ARK’s confidence in the synthetic biology company, which has been a recurring target for the fund’s investments.
The ARKK ETF also expanded its position in Natera Inc (NASDAQ:NTRA) by purchasing 55,623 shares, translating to an investment of around $8.75 million. This move suggests a growing interest in the genetic testing firm, as ARK has been accumulating shares in previous days.
Smaller but still significant buys included GitLab Inc (NASDAQ:GTLB) with 30,107 shares bought for approximately $1.37 million, and Personalis Inc (NASDAQ:PSNL) with 318,741 shares acquired within the ARKG ETF, totaling around $1.35 million. These investments reflect ARK’s ongoing strategy to invest in innovative tech and genomics companies.
Additionally, ARK made a minimal purchase of 100 shares of Pacific Biosciences of California Inc (NASDAQ:PACB) for a mere $111. While the dollar value was low, it’s worth noting that ARK has been actively trading PACB shares in recent sessions, suggesting a nuanced approach to managing its stake in the DNA sequencing company.
The ARKK ETF’s smallest transaction of the day was a buy of 20,532 shares of 10X Genomics Inc (NASDAQ:TXG), with a total dollar value of $176,780. This trade may not be substantial in dollar terms but is part of a broader pattern of investments in the life sciences technology company.
Cathie Wood’s ARK ETF’s daily trades indicate a strategic rebalancing of its portfolio, with a clear focus on companies positioned at the forefront of technological and biomedical innovation. Investors and market watchers will undoubtedly continue to monitor these trades closely, as they offer insight into ARK’s perspective on future industry trends and company prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.